AR107500A1 - Terapia de combinación de inhibidores de bromodominio y moduladores inmunitarios - Google Patents
Terapia de combinación de inhibidores de bromodominio y moduladores inmunitariosInfo
- Publication number
- AR107500A1 AR107500A1 ARP160103015A ARP160103015A AR107500A1 AR 107500 A1 AR107500 A1 AR 107500A1 AR P160103015 A ARP160103015 A AR P160103015A AR P160103015 A ARP160103015 A AR P160103015A AR 107500 A1 AR107500 A1 AR 107500A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- bromodomain inhibitor
- immune
- tautomer
- stereoisomer
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 6
- 238000002648 combination therapy Methods 0.000 title 1
- 229940125763 bromodomain inhibitor Drugs 0.000 abstract 11
- 239000013078 crystal Substances 0.000 abstract 7
- 229940002612 prodrug Drugs 0.000 abstract 7
- 239000000651 prodrug Substances 0.000 abstract 7
- 150000003839 salts Chemical class 0.000 abstract 7
- 239000012453 solvate Substances 0.000 abstract 7
- 101150051188 Adora2a gene Proteins 0.000 abstract 2
- -1 ICOS Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- LKEGXJXRNBALBV-PMCHYTPCSA-N 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-N-[4-[[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetyl]amino]butyl]acetamide Chemical group C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NCCCCNC(=O)COC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O LKEGXJXRNBALBV-PMCHYTPCSA-N 0.000 abstract 1
- VUVUVNZRUGEAHB-CYBMUJFWSA-N 7-(3,5-dimethyl-4-isoxazolyl)-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-3H-imidazo[4,5-c]quinolin-2-one Chemical group C1([C@@H](C)N2C3=C4C=C(C(=CC4=NC=C3NC2=O)C2=C(ON=C2C)C)OC)=CC=CC=N1 VUVUVNZRUGEAHB-CYBMUJFWSA-N 0.000 abstract 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 abstract 1
- 102100027207 CD27 antigen Human genes 0.000 abstract 1
- 102100038078 CD276 antigen Human genes 0.000 abstract 1
- 101710185679 CD276 antigen Proteins 0.000 abstract 1
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 102100025221 CD70 antigen Human genes 0.000 abstract 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 1
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 abstract 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 1
- 102100031351 Galectin-9 Human genes 0.000 abstract 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 abstract 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 abstract 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 abstract 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 abstract 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 abstract 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 abstract 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 abstract 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 abstract 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 abstract 1
- 102100034980 ICOS ligand Human genes 0.000 abstract 1
- 102000017578 LAG3 Human genes 0.000 abstract 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 abstract 1
- 102000004473 OX40 Ligand Human genes 0.000 abstract 1
- 108010042215 OX40 Ligand Proteins 0.000 abstract 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 abstract 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 abstract 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 abstract 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 abstract 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 abstract 1
- NETXMUIMUZJUTB-UHFFFAOYSA-N apabetalone Chemical group C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 NETXMUIMUZJUTB-UHFFFAOYSA-N 0.000 abstract 1
- QECMENZMDBOLDR-AWEZNQCLSA-N cpi 203 Chemical group N([C@@H](CC(N)=O)C1=NN=C(N1C=1SC(C)=C(C)C=11)C)=C1C1=CC=C(Cl)C=C1 QECMENZMDBOLDR-AWEZNQCLSA-N 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulga un método para tratar el cáncer en un sujeto que necesita el mismo, comprendiendo el método administrar al sujeto una cantidad terapéuticamente eficaz de un inhibidor de bromodominio; y, un modulador inmunitario. Reivindicación 11: El método de la reivindicación 9 ó 10, donde el inhibidor de bromodominio es JQ1 de fórmula (1), o una sal, solvato, hidrato, polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 12: El método de la reivindicación 9 ó 10, donde el inhibidor de bromodominio es Y803 de fórmula (2), o una sal, solvato, hidrato, polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 13: El método de la reivindicación 9 ó 10, donde el inhibidor de bromodominio es CPI-203 de fórmula (3), o una sal, solvato, hidrato, polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 14: El método de una cualquiera de las reivindicaciones 1 a 8, donde el inhibidor de bromodominio es dBET1 de fórmula (4) o una sal, solvato, hidrato, polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 17: El método de la reivindicación 15 ó 16, donde el inhibidor de bromodominio es IBET-151 de fórmula (5), o una sal, solvato, hidrato, polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 20: El método de la reivindicación 18 ó 19, donde el inhibidor de bromodominio es IBET-762 de fórmula (6), o una sal, solvato, hidrato, polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 23: El método de la reivindicación 21 ó 22, donde el inhibidor de bromodominio es RVX-208 de fórmula (7), o una sal, solvato, hidrato polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 37: El método de la reivindicación 36, donde la molécula inmunitaria estimuladora se selecciona entre el grupo que consiste en 4-1BB (CD137), CD137L, OX40, OX40L, ICOS, CD40, CD40L, CD70, CD27, CD28, CD80, CD86, B7RP1 y HVEM. Reivindicación 38: El método de una cualquiera de las reivindicaciones 1 a 35, donde el modulador inmunitario es un inhibidor de puntos de control inmunitarios. Reivindicación 39: El método de la reivindicación 39, donde el inhibidor de puntos de control inmunitarios es un inhibidor de una proteína de puntos de control inmunitarios seleccionada entre el grupo que consiste en: CTLA-4, PD-1, PDL-1, TIM3, LAG3, B7-H3, B7-H4, BTLA, GAL9 y A2aR. Reivindicación 49: El método de la reivindicación 39, donde el inhibidor de puntos de control inmunitarios es un inhibidor de A2aR. Reivindicación 50: El método de la reivindicación 49, donde el modulador inmunitario es un péptido, anticuerpo, ARN de interferencia, o molécula pequeña. Reivindicación 51: El método de la reivindicación 50, donde el modulador inmunitario es un anticuerpo monoclonal, o una proteína de fusión de Ig. Reivindicación 52: El método de la reivindicación 51, donde el modulador inmunitario es un anticuerpo anti-4-1BB. Reivindicación 53: El método de la reivindicación 51, donde el modulador inmunitario es un anticuerpo anti-PD-1. Reivindicación 54: El método de una cualquiera de las reivindicaciones 1 a 53, donde el inhibidor de bromodominio y el modulador inmunitario se administran al sujeto simultáneamente como una única composición. Reivindicación 60: El método de una cualquiera de las reivindicaciones 1 a 59, donde el inhibidor de bromodominio y el modulador inmunitario son sinérgicos en el tratamiento del cáncer, en comparación con el inhibidor de bromodominio en solitario o el modulador inmunitario en solitario.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236280P | 2015-10-02 | 2015-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107500A1 true AR107500A1 (es) | 2018-05-09 |
Family
ID=57137298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103015A AR107500A1 (es) | 2015-10-02 | 2016-09-30 | Terapia de combinación de inhibidores de bromodominio y moduladores inmunitarios |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190192532A1 (es) |
| EP (1) | EP3355922A2 (es) |
| JP (1) | JP2018530554A (es) |
| KR (1) | KR20180081507A (es) |
| CN (1) | CN108289957A (es) |
| AR (1) | AR107500A1 (es) |
| AU (1) | AU2016331190A1 (es) |
| BR (1) | BR112018006689A2 (es) |
| CA (1) | CA2999523A1 (es) |
| CL (1) | CL2018000853A1 (es) |
| HK (1) | HK1256269A1 (es) |
| IL (1) | IL258212A (es) |
| MA (1) | MA43037A (es) |
| MX (1) | MX2018003824A (es) |
| PE (1) | PE20181068A1 (es) |
| WO (1) | WO2017059319A2 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0611766A2 (pt) * | 2005-06-08 | 2011-12-20 | Dana Farber Cancer Institute | métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada |
| CA2723114C (en) | 2008-05-16 | 2018-02-27 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| EP2318435B1 (en) | 2008-08-28 | 2015-12-23 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc |
| CN103037865B (zh) | 2010-05-14 | 2014-10-29 | 达那-法伯癌症研究所 | 用于治疗瘤形成、炎性疾病和其他失调的化合物 |
| MX373121B (es) | 2010-05-14 | 2020-04-30 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| CA2879667C (en) | 2012-07-20 | 2021-11-16 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide |
| CA2929652A1 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| MX377534B (es) | 2014-02-28 | 2025-03-10 | Tensha Therapeutics Inc | Compuestos para usarse en el tratamiento de hiperinsulinemia. |
| US10124009B2 (en) | 2014-10-27 | 2018-11-13 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
| AU2017271588B2 (en) | 2016-05-27 | 2022-01-20 | Agenus Inc. | Anti-TIM-3 antibodies and methods of use thereof |
| IL323017A (en) | 2016-12-02 | 2025-10-01 | Htyr Acquisition Llc | Nanoparticle formulations |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| CN111892543A (zh) | 2018-01-16 | 2020-11-06 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制激酶活性的二苯氨基嘧啶类化合物 |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020051571A1 (en) * | 2018-09-07 | 2020-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Brd4-jak2 inhibitors |
| TWI816881B (zh) * | 2018-09-13 | 2023-10-01 | 大陸商恒翼生物醫藥（上海）股份有限公司 | 用於治療三陰性乳癌之組合療法 |
| BR112021010484A2 (pt) | 2018-11-30 | 2021-08-24 | Kymera Therapeutics, Inc. | Degradadores de irak e usos dos mesmos |
| CN109666723B (zh) * | 2019-01-22 | 2022-04-15 | 南通大学 | 一种基于pdl1/pdl2超增强子的免疫检测点抑制剂的应用 |
| AU2020272664A1 (en) | 2019-04-08 | 2021-11-04 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| EP3969041A4 (en) | 2019-05-14 | 2023-05-10 | Taiga Biotechnologies, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION |
| WO2021011634A1 (en) * | 2019-07-15 | 2021-01-21 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| ES3042146T3 (en) * | 2019-11-05 | 2025-11-18 | Resverlogix Corp | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| CN114981263B (zh) * | 2019-11-26 | 2024-12-24 | 贝诺生物有限公司 | 新型槲皮素氧化还原衍生物及作为bet抑制剂的用途 |
| CN115052627A (zh) | 2019-12-17 | 2022-09-13 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| AU2021300429A1 (en) | 2020-07-02 | 2023-02-16 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| AU2022220043A1 (en) | 2021-02-15 | 2023-08-31 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| WO2022182839A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| WO2023076556A1 (en) | 2021-10-29 | 2023-05-04 | Kymera Therapeutics, Inc. | Irak4 degraders and synthesis thereof |
| WO2023147594A2 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010314395B2 (en) * | 2009-11-05 | 2015-04-09 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| JP6022442B2 (ja) * | 2010-05-14 | 2016-11-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 男性用避妊組成物および使用方法 |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| CN103037865B (zh) * | 2010-05-14 | 2014-10-29 | 达那-法伯癌症研究所 | 用于治疗瘤形成、炎性疾病和其他失调的化合物 |
| US9249161B2 (en) * | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| CN105164135A (zh) * | 2013-02-22 | 2015-12-16 | 拜耳医药股份有限公司 | 4-取代的吡咯并二氮杂卓和吡唑并二氮杂卓 |
| HK1212972A1 (zh) * | 2013-02-22 | 2016-06-24 | Bayer Pharma Aktiengesellschaft | 作爲bet-蛋白抑制剂用於治疗过度增殖性疾病的吡咯并-和吡唑并-三唑并二氮杂卓 |
| WO2014144721A2 (en) * | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Treating th2-mediated diseases by inhibition of bromodomains |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| WO2015018521A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
| EP3054966A4 (en) * | 2013-10-11 | 2017-04-19 | Genentech, Inc. | Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy |
| LT3087071T (lt) * | 2013-12-24 | 2018-11-12 | Bristol-Myers Squibb Company | Tricikliniai junginiai kaip priešvėžiniai agentai |
-
2016
- 2016-09-30 PE PE2018000491A patent/PE20181068A1/es unknown
- 2016-09-30 KR KR1020187012018A patent/KR20180081507A/ko not_active Withdrawn
- 2016-09-30 EP EP16781957.2A patent/EP3355922A2/en not_active Withdrawn
- 2016-09-30 CN CN201680070462.8A patent/CN108289957A/zh active Pending
- 2016-09-30 US US15/764,131 patent/US20190192532A1/en not_active Abandoned
- 2016-09-30 HK HK18115329.0A patent/HK1256269A1/zh unknown
- 2016-09-30 MA MA043037A patent/MA43037A/fr unknown
- 2016-09-30 MX MX2018003824A patent/MX2018003824A/es unknown
- 2016-09-30 AR ARP160103015A patent/AR107500A1/es unknown
- 2016-09-30 AU AU2016331190A patent/AU2016331190A1/en not_active Abandoned
- 2016-09-30 WO PCT/US2016/054924 patent/WO2017059319A2/en not_active Ceased
- 2016-09-30 BR BR112018006689A patent/BR112018006689A2/pt not_active IP Right Cessation
- 2016-09-30 JP JP2018517255A patent/JP2018530554A/ja active Pending
- 2016-09-30 CA CA2999523A patent/CA2999523A1/en not_active Abandoned
-
2018
- 2018-03-19 IL IL258212A patent/IL258212A/en unknown
- 2018-04-02 CL CL2018000853A patent/CL2018000853A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180081507A (ko) | 2018-07-16 |
| WO2017059319A2 (en) | 2017-04-06 |
| MA43037A (fr) | 2018-08-08 |
| BR112018006689A2 (pt) | 2018-10-09 |
| CA2999523A1 (en) | 2017-04-06 |
| CN108289957A (zh) | 2018-07-17 |
| HK1256269A1 (zh) | 2019-09-20 |
| AU2016331190A1 (en) | 2018-04-12 |
| CL2018000853A1 (es) | 2018-08-31 |
| US20190192532A1 (en) | 2019-06-27 |
| IL258212A (en) | 2018-05-31 |
| JP2018530554A (ja) | 2018-10-18 |
| MX2018003824A (es) | 2019-04-01 |
| PE20181068A1 (es) | 2018-07-04 |
| WO2017059319A3 (en) | 2017-10-12 |
| EP3355922A2 (en) | 2018-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107500A1 (es) | Terapia de combinación de inhibidores de bromodominio y moduladores inmunitarios | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2018530554A5 (es) | ||
| WO2021247591A1 (en) | Antibodies to tigit | |
| US20230042913A1 (en) | A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf-kb ligand) antagonist for cancer therapy or prophylaxis and uses thereof | |
| JP2020514363A5 (es) | ||
| MY198034A (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
| EA034770B8 (ru) | Человеческие антитела к pd-1 | |
| CL2019003000A1 (es) | Proteínas de unión a antígenos trem2 y usos de estas. | |
| MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
| CN111163798A (zh) | 用于抗lag-3抗体的给药方案及其用途 | |
| JP2024105268A (ja) | 多重特異性抗体とその作製及び使用方法 | |
| MX378690B (es) | Terapias de combinacion. | |
| JP2019513725A5 (es) | ||
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| MX2009009636A (es) | Metodos para tratar enfermedades oftalmicas. | |
| RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
| JP2019530431A5 (es) | ||
| HRP20192346T1 (hr) | Molekule anti-lag-3 antitijela i njihove uporabe | |
| HRP20192285T1 (hr) | Anti-ox40 protutijela i postupci uporabe | |
| EP4286522A3 (en) | Fusion proteins of pd-1 and 4-1bb | |
| JP2020502147A5 (es) | ||
| WO2019246593A3 (en) | Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders | |
| CA3205985A1 (en) | Antibodies to tnfr2 and uses thereof | |
| CA3058262A1 (en) | Chimeric polypeptides and methods of altering the membrane localization of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |